BR112022012292A2 - Complexos de ferro e seus sais como agentes de contraste para mri - Google Patents
Complexos de ferro e seus sais como agentes de contraste para mriInfo
- Publication number
- BR112022012292A2 BR112022012292A2 BR112022012292A BR112022012292A BR112022012292A2 BR 112022012292 A2 BR112022012292 A2 BR 112022012292A2 BR 112022012292 A BR112022012292 A BR 112022012292A BR 112022012292 A BR112022012292 A BR 112022012292A BR 112022012292 A2 BR112022012292 A2 BR 112022012292A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- complex
- salt
- mri
- salts
- Prior art date
Links
- 239000002872 contrast media Substances 0.000 title abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical class [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 238000011065 in-situ storage Methods 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 150000004698 iron complex Chemical class 0.000 abstract 1
- 238000002595 magnetic resonance imaging Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/101—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
- A61K49/103—Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being acyclic, e.g. DTPA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
- C07F15/025—Iron compounds without a metal-carbon linkage
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Radiology & Medical Imaging (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
COMPLEXOS DE FERRO E SEUS SAIS COMO AGENTES DE CONTRASTE PARA MR. A presente invenção refere-se a um complexo de ferro com a fórmula geral (I) ou um seu sal farmaceuticamente aceitável. A presente invenção também se refere a uma composição farmacêutica formulada para administração oral e/ou parenteral, de preferência intravenosa, a referida composição farmacêutica sendo preferencialmente formulada como uma solução aquosa compreendendo o referido complexo ou sal. A presente invenção refere-se ainda ao referido complexo ou um seu sal ou à referida composição farmacêutica para uso como um agente de contraste para a imagiologia por ressonância magnética (MRI), bem como a um método e um kit para a preparação in situ do referido complexo ou sal e da referida composição farmacêutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102020000000922A IT202000000922A1 (it) | 2020-01-20 | 2020-01-20 | Complessi di ferro e relativi sali come agenti di contrasto per MRI |
| PCT/IB2021/050380 WO2021148939A1 (en) | 2020-01-20 | 2021-01-19 | Iron complexes and salts thereof as contrast agents for mri |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022012292A2 true BR112022012292A2 (pt) | 2022-08-30 |
Family
ID=70295815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022012292A BR112022012292A2 (pt) | 2020-01-20 | 2021-01-19 | Complexos de ferro e seus sais como agentes de contraste para mri |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230078638A1 (pt) |
| EP (1) | EP4093743A1 (pt) |
| JP (1) | JP2023510935A (pt) |
| KR (1) | KR20220130155A (pt) |
| CN (1) | CN114981282B (pt) |
| AU (1) | AU2021209424A1 (pt) |
| BR (1) | BR112022012292A2 (pt) |
| CA (1) | CA3162611A1 (pt) |
| IL (1) | IL294883A (pt) |
| IT (1) | IT202000000922A1 (pt) |
| WO (1) | WO2021148939A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114272394A (zh) * | 2021-12-28 | 2022-04-05 | 中山大学孙逸仙纪念医院 | 一种纳米探针的构建与应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY129541A (en) | 1996-06-25 | 2007-04-30 | Novartis Ag | Substituded 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators |
-
2020
- 2020-01-20 IT IT102020000000922A patent/IT202000000922A1/it unknown
-
2021
- 2021-01-19 IL IL294883A patent/IL294883A/en unknown
- 2021-01-19 CA CA3162611A patent/CA3162611A1/en active Pending
- 2021-01-19 EP EP21706389.0A patent/EP4093743A1/en active Pending
- 2021-01-19 AU AU2021209424A patent/AU2021209424A1/en active Pending
- 2021-01-19 KR KR1020227027369A patent/KR20220130155A/ko active Search and Examination
- 2021-01-19 CN CN202180009843.6A patent/CN114981282B/zh active Active
- 2021-01-19 BR BR112022012292A patent/BR112022012292A2/pt unknown
- 2021-01-19 US US17/793,459 patent/US20230078638A1/en active Pending
- 2021-01-19 JP JP2022543662A patent/JP2023510935A/ja active Pending
- 2021-01-19 WO PCT/IB2021/050380 patent/WO2021148939A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023510935A (ja) | 2023-03-15 |
| CA3162611A1 (en) | 2021-07-29 |
| IT202000000922A1 (it) | 2021-07-20 |
| CN114981282A (zh) | 2022-08-30 |
| WO2021148939A1 (en) | 2021-07-29 |
| EP4093743A1 (en) | 2022-11-30 |
| KR20220130155A (ko) | 2022-09-26 |
| IL294883A (en) | 2022-09-01 |
| AU2021209424A1 (en) | 2022-07-07 |
| CN114981282B (zh) | 2024-02-23 |
| US20230078638A1 (en) | 2023-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Andrei et al. | FDA approved antibacterial drugs: 2018-2019 | |
| BR112016028345A2 (pt) | composto, composição farmacêutica, métodos para inibir agregação de tau em um mamífero e para avaliar depósitos de tau em um paciente, e, uso de um composto. | |
| Remeš et al. | Intraventricular and lumbar intrathecal administration of antibiotics in postneurosurgical patients with meningitis and/or ventriculitis in a serious clinical state | |
| WO2004035522A1 (ja) | プリオン蛋白蓄積性疾患の診断プローブおよび治療薬ならびにプリオン蛋白の染色剤 | |
| BR112023017197A2 (pt) | Agente de contraste para uso em formação de imagem por ressonância magnética | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112022012292A2 (pt) | Complexos de ferro e seus sais como agentes de contraste para mri | |
| BR112015029401A2 (pt) | derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças | |
| US10722550B2 (en) | Compositions and methods for the treatment of fungal infections | |
| JP2008515821A (ja) | 薬物誘発性細胞毒性の予防のための化合物の使用 | |
| Früh et al. | Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08) | |
| TW201716056A (zh) | 藥學組成物 | |
| JP2012525391A5 (pt) | ||
| Kadiyala et al. | Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate | |
| Yu et al. | Intraventricular colistin sulphate as a last resort therapy in a patient with multidrug‐resistant Acinetobacter baumannii induced post‐neurosurgical ventriculitis | |
| JP2019123731A5 (pt) | ||
| US11452735B2 (en) | Pharmaceutical combinations of organo-arsenoxide compounds and mTOR inhibitors | |
| JPWO2009031577A1 (ja) | 注射剤、注射液および注射用キット製剤 | |
| JP2019535830A (ja) | 造影剤誘発急性腎障害の予防および／または処置 | |
| CN103933044B (zh) | 一种治疗肿瘤的药物组合物及用途 | |
| CN102781451A (zh) | 使用头孢洛林用于治疗细菌感染的组合物和方法 | |
| Chaudhary et al. | Efficacy of cefixime in the treatment of typhoid fever | |
| JP2013507443A5 (pt) | ||
| CN112353804B (zh) | Yl-0919在制备抗感染或感染相关疾病的药物中的应用 | |
| RAIZISS et al. | Chemotherapeutic studies concerning the penetration of organic compounds of arsenic into the cerebrospinal system |